Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ONC201 + Atezolizumab for Endometrial Cancer
Recruiting1 awardPhase 1
Chapel Hill, North Carolina
This trial is testing a combination of two drugs, atezolizumab and ONC201, to treat women with advanced endometrial cancer who haven't responded to other treatments. Atezolizumab boosts the immune system to fight cancer, while ONC201 stops cancer cells from growing.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service